Ron, would that have anything to do with Linzness being approved for three indications (CIC, IBS, OIC) and Plecanatide on the verge of only being approved for one (CIC)?
No one can possibly guess what is going on with this stock or company. To say that it could be $5-$6 means that you just haven't been paying attention. The only thing certain with this stock is that nothing is certain.
Adam, what is different about it? Besides always trying to get your name at the top of the message boards, could you expand on what you are referring to?
Are we planning to initiate a phase II for UC this year? I really think that is the backbone of big money right there. Anyone know? I didn't see anything in the goals for the company mentioning that.
getting a little nervous on a potential delay. They have continued to maintain their January NDA.
10,125 shares at 4.50. Just want a buyout asap as I have been in this thing much longer than I should have been.
I agree as those were pretty generic statements. Being only a 4 week trial, and hearing that the results were clearly noticeable is very encouraging. Having only 28 patients, however, doesn't give us a reliable sample. He didn't allude to the numbers of people impacted or anything either. I think it would have been much more exciting if they were pushing to start a phase II ASAP. Getting successful results on a Phase II, especially if they were to get a lot of patients like they did in the Plecanatide trials, would assure a buyout and increase it's value significantly.
Just curious if management has given any indication for what they feel Zalviso could do in Europe for the first full qtr it is introduced in Europe? I think that carries a lot of weight not only for helping with much needed revenue, but also setting the stage for how well this drug could do as in the future. Any plans to get the ARX-04 reviewed this year in Europe?
02 and 03 have not been discussed much. What was the number of people in their trials? I think things are at a standstill until at least we see how the reception and numbers look for the first full quarter of Zalviso's intro to Europe. I wish we would start a phase III for either 02 or 03, but being cash strapped doesn't help us much.